60 Degrees Pharmaceuticals (SXTP) Competitors $1.34 +0.02 (+1.52%) (As of 12/26/2024 05:36 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SXTP vs. RLMD, CLRB, ENSC, TLPH, APLM, MYNZ, CSCI, VIRX, KPRX, and INDPShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Relmada Therapeutics (RLMD), Cellectar Biosciences (CLRB), Ensysce Biosciences (ENSC), Talphera (TLPH), Apollomics (APLM), Mainz Biomed (MYNZ), COSCIENS Biopharma (CSCI), Viracta Therapeutics (VIRX), Kiora Pharmaceuticals (KPRX), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical preparations" industry. 60 Degrees Pharmaceuticals vs. Relmada Therapeutics Cellectar Biosciences Ensysce Biosciences Talphera Apollomics Mainz Biomed COSCIENS Biopharma Viracta Therapeutics Kiora Pharmaceuticals Indaptus Therapeutics Relmada Therapeutics (NASDAQ:RLMD) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Is RLMD or SXTP more profitable? 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% 60 Degrees Pharmaceuticals N/A N/A -113.43% Does the media refer more to RLMD or SXTP? In the previous week, 60 Degrees Pharmaceuticals had 8 more articles in the media than Relmada Therapeutics. MarketBeat recorded 9 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Relmada Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.46 beat Relmada Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Neutral 60 Degrees Pharmaceuticals Neutral Do analysts rate RLMD or SXTP? Relmada Therapeutics presently has a consensus target price of $4.25, suggesting a potential upside of 1,073.38%. Given Relmada Therapeutics' higher probable upside, research analysts clearly believe Relmada Therapeutics is more favorable than 60 Degrees Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.0060 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, RLMD or SXTP? Relmada Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 5.36, suggesting that its share price is 436% more volatile than the S&P 500. Does the MarketBeat Community favor RLMD or SXTP? Relmada Therapeutics received 16 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 37.78% of users gave Relmada Therapeutics an outperform vote while only 11.11% of users gave 60 Degrees Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% 60 Degrees PharmaceuticalsOutperform Votes111.11%Underperform Votes888.89% Which has better earnings & valuation, RLMD or SXTP? 60 Degrees Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.87-0.1360 Degrees Pharmaceuticals$502.41K6.13-$3.77M-$10.08-0.13 Do institutionals & insiders hold more shares of RLMD or SXTP? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryRelmada Therapeutics beats 60 Degrees Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08M$6.68B$5.23B$9.26BDividend YieldN/A2.98%5.11%4.26%P/E Ratio-0.1310.6487.0417.34Price / Sales6.13208.911,150.35123.93Price / CashN/A57.1543.2337.88Price / Book-0.135.254.895.06Net Income-$3.77M$150.75M$120.15M$225.13M7 Day Performance6.35%4.45%2.97%4.21%1 Month Performance22.94%-3.67%17.12%3.06%1 Year Performance13.56%7.60%27.94%17.91% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals1.0845 of 5 stars$1.34+1.5%N/A+16.5%$3.08M$502,409.00-0.133Short Interest ↑RLMDRelmada Therapeutics3.9064 of 5 stars$0.36-0.3%$4.25+1,074.7%-89.0%$10.92MN/A-0.1310Short Interest ↑CLRBCellectar Biosciences1.9775 of 5 stars$0.26+12.4%$17.67+6,589.4%-88.2%$10.90MN/A-0.1510Short Interest ↑Gap UpHigh Trading VolumeENSCEnsysce Biosciences0.5753 of 5 stars$8.31+2.6%N/A-40.6%$10.85M$2.23M-0.3010Short Interest ↓Gap DownTLPHTalphera2.6635 of 5 stars$0.62-2.4%$4.50+625.8%N/A$10.56M$281,000.00-0.9019Short Interest ↑Negative NewsGap DownAPLMApollomics2.7665 of 5 stars$9.62-1.3%$200.00+1,979.0%-87.3%$10.46M$1.22M0.0045Short Interest ↓MYNZMainz Biomed1.7737 of 5 stars$5.13-23.2%$120.00+2,239.2%-90.5%$10.27M$917,203.00-0.0830Short Interest ↑High Trading VolumeCSCICOSCIENS BiopharmaN/A$2.69+7.6%N/AN/A$10.11M$7.60M-0.23N/AVIRXViracta Therapeutics2.1082 of 5 stars$0.25+18.1%$5.00+1,916.1%-56.0%$9.86MN/A-0.2320Analyst ForecastShort Interest ↑News CoverageGap UpKPRXKiora Pharmaceuticals3.6064 of 5 stars$3.27flat$10.00+205.8%-33.4%$9.81M$16M0.0010Short Interest ↓INDPIndaptus Therapeutics3.2057 of 5 stars$0.90-4.0%$8.50+844.3%-51.8%$9.18MN/A-0.536Gap Down Related Companies and Tools Related Companies RLMD Competitors CLRB Competitors ENSC Competitors TLPH Competitors APLM Competitors MYNZ Competitors CSCI Competitors VIRX Competitors KPRX Competitors INDP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SXTP) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
